A simple and highly selective spectrophotometric method has been developed for the determination of selegiline hydrochloride in bulk and formulations. Method A is based on the oxidation of 3-methyl-2-benzothiazolinone hydrazone in the presence of ceric ammonium sulphate, followed by its coupling reaction with drug to form a colored product having of 629?nm. Method B is based on the coupling reaction of drug with 4-aminoantipyrine to give a new ligand that reacts with copper(II) to give intense bluish red colored chelate which is measured at 539?nm. Beer’s law is obeyed in the range of 10.00–85.00?μg?mL?1 with molar absorptivity of for method A and 20.00–120.00?μg?mL?1 with molar absorptivity of for method B. The optimum reaction condition and the analytical parameters are evaluated. The results obtained indicate that the methods are free from interference of the ingredients; thus they are successfully applied to pharmaceutical formulations. 1. Introduction Selegiline hydrochloride (SGE) (Figure 1) (deprenyl), [(R)-(2)-N-methyl-(1-phenyl-2-propyl)-N-propinylamine] hydrochloride [1], is a levomethamphetamine derivative which belongs to a class of drugs called phenethylamines [2]. SEG is a selective, irreversible inhibitor of monoamine oxidase (MAO-A) [3]. It is used for the treatment of early-stage Parkinson’s disease, depression, and senile dementia [4]. It is useful adjunct in the treatment of cocaine addiction [5]. SEG (brand name Anipryl) is also used (at extremely high dosages relative to humans) in veterinary medicine to treat the symptoms of Cushing’s disease and cognitive dysfunction (canine cognitive dysfunction) in dogs [6]. Recommended dosage of SEG is about 10?mg/day; further increase in the dosage will lead to the nonselective inhibition of MAO [7]. Therefore, it is essential to develop a standard analytical method for monitoring residual drug in bulk and in pharmaceutical formulations. The pharmaceutical importance of drug has prompted us to devise methods for the rapid determination of SEG. A very few methods are reported in the literature for the determination of SEG in pharmaceutical formulations which include high performance liquid chromatography [8–12], gas chromatography [13, 14], fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC/MS) [15], spectrofluorometry [16], and stereoselective analyses [17]. The literature survey reveals that so far there is no visible spectrophotometric method for the analysis of SEG. Figure 1: Chemical structure of SEG. Unlike gas chromatograph and high performance
References
[1]
W. Birkmayer, J. Knoll, P. Riederer, and M. B. Youdim, “(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease,” Modern problems of pharmacopsychiatry, vol. 19, pp. 170–176, 1983.
[2]
A. Clarke, F. Brewer, E. S. Johnson et al., “A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition,” Journal of Neural Transmission, vol. 110, no. 11, pp. 1241–1255, 2003.
[3]
J. Birks and L. Flicker, “Selegiline for Alzheimer's disease,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD00044, 2003.
[4]
H. Allain, J. Cougnard, and H.-C. Neukirch, “Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT),” Acta Neurologica Scandinavica, Supplement, vol. 84, no. 136, pp. 73–78, 1991.
[5]
J. D. Amsterdam, “A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder,” Journal of Clinical Psychiatry, vol. 64, no. 2, pp. 208–214, 2003.
[6]
B. G. Katzung, Basic & Clinical Pharmacology, Lange Medical Books, McGraw-Hill, New York, NY, USA, 9th edition, 2004.
[7]
J. A. Braddock, D. B. Church, I. D. Robertson, and A. D. J. Watson, “Inefficacy of selegiline in treatment of canine pituitary-dependent hyper-adrenocorticism,” Australian Veterinary Journal, vol. 82, no. 5, pp. 272–277, 2004.
[8]
S. Pichini, R. Pacifici, M. Pellegrini et al., “Development and validation of a high-performance liquid chromatography—mass spectrometry assay for determination of amphetamine, methamphetamine, and methylenedioxy derivatives in meconium,” Analytical Chemistry, vol. 76, no. 7, pp. 2124–2132, 2004.
[9]
K. Nishida, S. Itoh, N. Inoue, K. Kudo, and N. Ikeda, “High-performance liquid chromatographic-mass spectrometric determination of methamphetamine and amphetamine enantiomers, desmethylselegiline and selegiline, in hair samples of long-term methamphetamine abusers or selegiline users,” Journal of Analytical Toxicology, vol. 30, no. 4, pp. 232–237, 2006.
[10]
M. H. Slawson, J. L. Taccogno, R. L. Foltz, and D. E. Moody, “Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry,” Journal of Analytical Toxicology, vol. 26, no. 7, pp. 430–437, 2002.
[11]
R. La Croix, E. Pianezzola, and M. S. Benedetti, “Sensitive high-performance liquid chromatographic method for the determination of the three main metabolites of selegiline (L-deprenyl) in human plasma,” Journal of Chromatography B, vol. 656, no. 1, pp. 251–258, 1994.
[12]
M. Katagi, M. Tatsuno, A. Miki, M. Nishikawa, K. Nakajima, and H. Tsuchihashi, “Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry,” Journal of Chromatography B, vol. 759, no. 1, pp. 125–133, 2001.
[13]
G. Szebeni, J. Lengyel, G. Szekacs, K. Magyar, J. Gaal, and I. Szatmari, “Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine, methamphetamine and demethyl-deprenyl in pig plasma,” Acta Physiologica Hungarica, vol. 83, no. 2, pp. 135–141, 1995.
[14]
K. S. Patrick, B. Lan Nguyen, and J. D. McCallister, “Gas chromatographic-mass spectrometric determination of plasma selegiline using a deuterated internal standard,” Journal of Chromatography, vol. 583, no. 2, pp. 254–258, 1992.
[15]
H. H. Maurer and T. Kraemer, “Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine,” Archives of Toxicology, vol. 66, no. 9, pp. 675–678, 1992.
[16]
J. Netriová, J. Sádecká, and I. Ska?áni, “Spectrofluorimetric determination of selegiline,” Farmaceuticky Obzor, vol. 74, no. 7, pp. 181–186, 2005.
[17]
M. Hasegawa, K. Matsubara, S. Fukushima, C. Maseda, T. Uezono, and K. Kimura, “Stereoselective analyses of selegiline metabolites: possible urinary markers for selegiline therapy,” Forensic Science International, vol. 101, no. 2, pp. 95–106, 1999.
[18]
R. G. Vijaya, Y. Triveni, K. Divya, N. K. Lakshmi, and G. G. Venu, “Application of MBTH and sulphanilic acid for the quantitative spectrophotometric determination of diacerein in bulk and formulations,” Der Pharma Chemica, vol. 1, no. 2, pp. 285–229, 2009.
[19]
E. Sawicki, T. W. Stanley, T. R. Hauser, W. Elbert, and J. L. Noe, “Spot test detection and colorimetric determination of aromatic amines and imino heteroaromatic compounds with 3-methyl-2-benzothiazolone hydrazone,” Analytical Chemistry, vol. 33, no. 6, pp. 722–725, 1961.
[20]
N. Theia Al-Sabha, “Spectrophotometric assay of phenylephrine hydrochloride using 4-aminoantipyrine and copper (II),” Pakistan Journal of Analytical and Environmental Chemistry, vol. 11, no. 1, pp. 01–07, 2010.
[21]
International Conference on Harmonization (ICH) Guidelines, http://www.ICH.org/.
[22]
G. D. Christian and J. E. O'Rilly, “Jobs method,” in Instrumental Analysis, Prentice Hall, Upper Saddle River, NJ, USA, 2nd edition, 1980.